Core Vct I Share Discussion Threads

[nicosevos] 17/1/2018 14:43

MYN.....

tidy 2 17 Jan '18 - 13:48 - 1985 of 1986 0 2 0

RT AlignResearch "Ref Mayan Energy #MYN - we have spoken with Chairman charlieawood and have had confirmed that speculation of an imminent placing in the stock is wholly misplaced. We are taking advantage of weakness in attempting to add to our position. #alignment TexasEddieG"

[nicosevos] 17/1/2018 14:42

MYN.....

tidy 2 17 Jan '18 - 13:48 - 1985 of 1986 0 2 0

RT AlignResearch "Ref Mayan Energy #MYN - we have spoken with Chairman charlieawood and have had confirmed that speculation of an imminent placing in the stock is wholly misplaced. We are taking advantage of weakness in attempting to add to our position. #alignment TexasEddieG"

[andrbea] 17/1/2018 13:31

large trade (buy?) on mka today (625k shares = £72k)

[hottingup] 17/1/2018 10:38

Shares Magazine
Small caps poised for big news in 2018:
We look at 19 stocks primed to deliver major events in their career
21/12/2017



"Drug developer ImmuPharma (IMM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators."


This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
Tue. 26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupuzor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

[garbut] 17/1/2018 08:18

DEMG!
Cannot buy 50 quids worth after that RNS!!
Deltex Medical!

[market master] 17/1/2018 08:13

#DKE very tight spread with the bid higher than the offer:

Bid 0.41
Ask 0.409

After a flurry of large buys yesterday around 9 million buys

[brasso3] 16/1/2018 07:47

" With this change, our sum of the parts valuation for Mayan Energy has increased to £65.45 million and which suggests a price of 5.21p per shares on a fully diluted basis per the table below:"

[brasso3] 15/1/2018 17:47

Golden Cross about to form on the MYN chart. I reckon we are talking 3 - 5 trading sessions before that happens. :)

[fillipe] 15/1/2018 16:29

PREM - firming into the close.

f

[eye2] 15/1/2018 14:48

MYN looks one of the best charts ive seen for a while

[brasso3] 15/1/2018 13:45

MYN (Mayan Energy) just gone through the 200 DMA. Ready to pop with a broker note expected tomorrow. 8 Workovers to be complete before the end of February. Market cap = £8m.

Currently 0.79p with a broker upgrade expected (previous target was 2.1p)

[yawn3] 15/1/2018 09:07

BNR

Starting to see some interest. Could bounce from here.

[yawn3] 15/1/2018 08:03

GGP

Oh dear.

[cpap man] 13/1/2018 11:30

WRES



Look at the share price performance and the growing bullish chart patterns for WRES

[cpap man] 13/1/2018 11:26

What have ADVFN done with their BB's?!?!?

[yawn3] 12/1/2018 14:39

GUN

Tick Tick

[fillipe] 12/1/2018 12:03

TAVI recovering well from its November 2017 drop. I've put a note on their board.

f

[cpap man] 12/1/2018 10:51

OTC



Ortac Resources* (OTC LN) 2.5p, Mkt Cap 8.3m – Name change to Arc Minerals

(new ticker ARC LN) (Ortac an effective 49.9% stake in the Akyanga project)

Ortac Resources has announced that it is changing its name, with immediate effect, to Arc Minerals which will now trade under the ticker ARCM LN.

Over the recent past, Ortac has identified a clear, African focussed, strategy and brought in experienced management with relevant expertise to reflect the shift in emphasis away from its previous Slovakian focus.

Commenting on the change, Executive Chairman, Nick von Schirnding said “The renaming of the group to Arc Minerals represents an exciting new chapter for us. This follows a number of material changes that have been implemented over the past few months including executing a clear strategy focusing on our high quality African exploration assets”.

Recent drilling at Akyanga (part of Missisi) appears to be extending the footprint of the known mineralisation in the DRC leading to better definition and expansion of the gold resource.

Zamsort: in Zambia, the company is “now actively pursuing discussions with fellow stakeholders at Zamsort, which is an attractive Zambian copper/cobalt asset.”

Conclusion: The change of name comes as the company moves towards a new phase focussed on its African projects.

*SP Angel acts as nomad and broker to Ortac Resources. Ortac holds 84.7% of CASA Mining which holds 71.25% of the Misisi Gold project in South Kivu in the Eastern part of the DRC. This gives Ortac an effective 49.9% stake in the Akyanga project. Ortac also holds a 14% stake in Zamsort which rises to 19.35% on conversion of a 8% Secured Convertible Loan notes which are convertible at Ortac’s option.

[cpap man] 12/1/2018 08:15

UOG



maverick24712 Jan '18 - 07:37 - 83 of 84

Flow testing commenced
Results next week
Expecting new deal soon too from recent fundraise

[cpap man] 12/1/2018 08:12

OTC



maverick24711 Jan '18 - 22:47 - 898 of 900

Great update on all fronts looks like sturec close to a sale too and news to come on zamsort

[cpap man] 12/1/2018 07:56

OTC



ORTAC RESOURCES LTD

("ORTAC" or the "COMPANY")



Notice of Name Change



Ortac Resources is pleased to announce that the Company has changed its name to Arc Minerals Ltd ("Arc Minerals") with immediate effect. The Company's new ticker will be ARCM.LN and trading under the new name is expected to commence on or around 22 January 2018. The Company's new website address is www.arcminerals.com.



Nick von Schirnding, executive chairman commented: "The renaming of the group to Arc Minerals represents an exciting new chapter for us. This follows a number of material changes that have been implemented over the past few months including executing a clear strategy focusing on our high quality African exploration assets. Having made major strides in consolidating and advancing our highly attractive gold prospect at Casa, we are now actively pursuing discussions with fellow stakeholders at Zamsort, which is an attractive Zambian copper/cobalt asset. With a new and highly experienced board of directors in place we look forward to an exciting future as Arc Minerals ."

[cpap man] 12/1/2018 07:52

UOG



United Oil & Gas Plc

Podere Maiar flow testing commences



United Oil & Gas Plc ("UOG", "United" or the "Company"), the London Stock Exchange listed oil and gas exploration and development company, announces that flow testing has commenced on the Podere Maiar 1 ("PM1") well on the Selva Gas Field in the Podere Gallina licence.



The Company is pleased to announce that it has been informed by the operator that flow testing on the PM1 well in Northern Italy has commenced today, and results will be reported next week.

[3rd eye] 11/1/2018 16:26

BOO....the FT on BOO

[3rd eye] 11/1/2018 16:26

BOO....the FT on BOO